Truist Financial Has Lowered Expectations for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

06 Nov 2026, 18:01 by Mitch Edgeman · The Markets Daily

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target lowered by Truist Financial from $37.00 to $35.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial‘s price target points to a potential upside of 19.64% from the company’s previous close.

A number of other equities analysts have also commented on AGIO. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. JPMorgan Chase & Co. boosted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Citigroup upped their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, HC Wainwright raised their target price on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.12.

Check Out Our Latest Report on Agios Pharmaceuticals

Agios Pharmaceuticals Price Performance

Shares of AGIO stock traded up $0.98 during trading on Friday, reaching $29.25. The company had a trading volume of 439,928 shares, compared to its average volume of 1,073,670. The firm’s 50 day simple moving average is $33.37 and its two-hundred day simple moving average is $31.75. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The company has a market capitalization of $1.75 billion, a PE ratio of -4.16 and a beta of 0.66.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.15. The firm had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. Analysts forecast that Agios Pharmaceuticals will post -5.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the sale, the insider owned 54,645 shares of the company’s stock, valued at $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 9,855 shares of company stock valued at $371,112. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth about $239,582,000. Assenagon Asset Management S.A. increased its position in Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after acquiring an additional 1,782,457 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $47,800,000. Parkman Healthcare Partners LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $24,828,000. Finally, SCS Capital Management LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter worth about $22,743,000.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

Positive Sentiment: HC Wainwright raised its price target to $62 from $55 and reiterated a Buy rating, signaling greater confidence in Agios’ prospects. HC Wainwright ratings
Positive Sentiment: Agios beat Q3 estimates, reporting a loss of $1.09 per share versus the $1.24 consensus and revenue of $55.39 million versus expectations of $51.65 million. The loss also narrowed from $1.78 per share a year earlier. Agios Q3 results and business update
Positive Sentiment: Mitapivat revenue increased more than fourfold, pointing to strong commercial momentum for the drug. Mitapivat revenue and FDA timeline
Neutral Sentiment: The FDA decision on mitapivat for sickle cell disease is expected in February 2027. The timeline gives investors a milestone to watch, though approval remains uncertain. Mitapivat revenue and FDA timeline
Negative Sentiment: Agios plans to eliminate more than 100 R&D roles, a significant restructuring that could raise concerns about research capacity even as it may reduce costs. Agios R&D job cuts

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.